Gilead buys cell therapy partner Arcellx for up to $7.8bn Gilead has shored up its position in cell therapies with a deal to acquire Arcellx, taking full control of their partnered multiple myeloma CAR-T.

#Gilead #celltherapy #Arcellx #GileadSciences #celltherapies #cancer #oncology #CARTtherapy #multiplemyeloma #Anitocel #CARexpression #BCMAtarget #BCMAdirectedCARTs #relapsedmultiplemyeloma #refractorymultiplemyeloma #iMMagine1study #multiplemyelomapatients #BCMAbindertechnology
zurl.co/iWAbv

ギリアドとカイト、ASH 2025でCAR-T療法の新データ発表 | STELLANEWS.LIFE ギリアドとカイトはASH 2025で、多発性骨髄腫向けCAR-T療法「アニトセル」や大型B細胞リンパ腫向け「Yescarta」などの新データを発表。外来投与可能性も注目。

Gilead and Kite Showcase Continued Progress in Transforming Blood Cancer Care With New Cell Therapy Data at ASH 2025
stellanews.life/technology_c...

#CARTtherapy #BloodCancer #Gilead #KitePharma #AnitoCel #MultipleMyeloma #DLBCL #ASH2025 #CellTherapy #iMMagine1